Novartis Ag

Yu Gai

Feng Gao

Jianguang Zhou

Weiyong Kong

Can Wang

Xianglin Zhao

Benjamin Martin

Zhongcheng Min

Chutian Shu

Yi Zhao

Jibin Zhao

Ruidong Wang

Shaofeng Rong

Yadong Lu

Peng Fu

Stefan Peukert

Frederic Zecri

Fabrice Gallou

Atwood Kim Cheung

Rui Zheng

Donglei Liu

Qian Liu

Xin Chen

Pengfei Guo

Yizong Zhou

Sejal Patel

Michael Parmentier

Justin Mao

Tyler Harrison

Rohit Duvadie

Jay Larrow

Heng Ge

Xingjuan Chang

Yiping Ding

Jiong Ye

Xuchun Zheng

The invention relates to a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein A, Rand Rare as described herein, as well as compositions and methods of using such compounds.

Naphthyridinone derivatives for the treatment of a disease or disorder

The present invention relates to a method of synthesizing a compound of formula (I) also referred to as 4-(((2S,4S)-(4-ethoxy-1-(((5-methoxy-7-methyl-1H-indol-4-yl)methyl)piperidin-2-yl))benzoic acid, or a pharmaceutically acceptable salt thereof, and/or intermediates thereof, their use as pharmaceuticals and pharmaceutical compositions and the use of intermediates for preparing a compound of formula (I), or a pharmaceutically acceptable salt thereof.

Chemical process for preparing phenylpiperidinyl indole derivatives

The present invention is directed to aqueous reaction mixtures for enzymatic synthesis reactions comprising a surfactant. The surfactant in the reaction mixture increases stability and yield of the enzymatic reaction. Furthermore, method for performing an enzymatic reaction using said aqueous reaction mixtures are provided.

Enzymatic reaction medium containing surfactant

The present invention relates to a method of synthesizing a compound of formula (I) also referred to as 4-((2S,4S)-(4-ethoxy-1-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)piperidin-2-yl))benzoic acid, or a pharmaceutically acceptable salt thereof, and/or intermediates thereof, their use as pharmaceuticals and pharmaceutical compositions and the use of intermediates for preparing a compound of formula (I), or a pharmaceutically acceptable salt thereof.

The invention relates to compounds of formula (I): useful for treating disorders mediated by acyl coA-diacylglycerol acyl transferase 1 (DGAT1), e.g. metabolic disorders. The invention also provides methods of treating such disorders, and compounds and compositions etc. for their treatment.

Cyclic bridgehead ether DGAT1 inhibitors

Growing community of inventors

Jiangsu, China

Yu Gai